ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk of infection and other patients at risk of certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics, including BIVIGAM® (Immune Globulin Intravenous, Human), ASCENIV™ (Immune Globulin Intravenous, Human – slra 10% Liquid) and NABI-HB® (Hepatitis B Immune Globulin, Human). The company also operates a network of ADMA BioCenters plasma collection facilities in the U.S., which provide a portion of its raw material plasma.
The headquarters serves as the central hub for corporate operations, including executive leadership, strategic planning, finance, legal, business development, and oversight of research, development, and commercial activities.
The facility is a modern corporate office space designed to support the company's administrative and strategic functions. Specific architectural details are not widely publicized, but it aligns with standard biopharmaceutical corporate environments.
The work culture at ADMA Biologics headquarters likely emphasizes innovation, scientific rigor, collaboration, and a strong focus on patient needs, driven by its mission to provide life-saving therapies. Employees often come from scientific, medical, and business backgrounds dedicated to advancing healthcare.
The Ramsey headquarters is significant as it centralizes ADMA's core decision-making processes and corporate governance, enabling efficient management of its expanding biopharmaceutical operations, including manufacturing and plasma collection.
ADMA Biologics primarily operates within the United States. Its manufacturing, plasma collection (ADMA BioCenters), research, development, and commercialization efforts are focused on the U.S. market for its specialized plasma-derived biologics. While its products address critical medical needs, its operational footprint and direct sales are currently U.S.-centric.
465 State Route 17
Ramsey
New Jersey
USA
Address: 5800 Park of Commerce Blvd. N.W., Boca Raton, FL 33487
Serves as the primary manufacturing site, critical for the production and supply of ADMA's commercial biologic therapies for the U.S. market.
Address: Multiple ADMA BioCenters plasma collection facilities across states like Georgia, Tennessee, North Carolina, South Carolina, etc. (e.g., 2675 Ben King Road, Kennesaw, GA 30144)
Strategically located to ensure a consistent and reliable supply of source plasma to support ADMA's manufacturing needs and product pipeline.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ADMA Biologics' leadership includes:
ADMA Biologics has been backed by several prominent investors over the years, including:
ADMA Biologics strengthened its executive team with the appointment of a new Chief Medical Officer in the past year. No major C-suite departures were publicly announced during this period.
Discover the tools ADMA Biologics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ADMA Biologics likely utilizes common corporate email formatting conventions. The most probable formats involve a combination of the employee's first name and last name followed by the '@admabiologics.com' domain.
[first_initial][last]@admabiologics.com
Format
agrossman@admabiologics.com
Example
80%
Success rate
GlobeNewswire • May 6, 2024
ADMA Biologics announced record financial results for Q1 2024, with total revenues of $81.8 million, a 52% increase year-over-year. The company achieved its first GAAP profitable quarter and raised its full-year 2024 revenue guidance to $330-$360 million....more
GlobeNewswire • February 28, 2024
ADMA Biologics reported record financial results for Q4 and full-year 2023, including total revenues of $258.2 million for the full year, an 86% increase compared to 2022. The company highlighted strong growth in its immunoglobulins franchise and plasma center network expansion....more
GlobeNewswire • May 22, 2023
ADMA Biologics announced the appointment of Dr. Young T. Kim as its Chief Medical Officer. Dr. Kim brings over 20 years of experience in clinical development, medical affairs, and pharmacovigilance within the biopharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ADMA Biologics, are just a search away.